The Lancet, Volume 375, Issue 9719 , Pages 963 – 964, 20 March 2010
By: Peter S. Bach
The 2006 approval of Merck’s human papillomavirus (HPV) vaccine (Gardasil) by the US Food and Drug Administration (FDA) exemplified the potential of bench-to-bedside research. This vaccine against the virus that causes cervical cancer received immediate recommendation by the Advisory Committee on Immunization Practices at the US Centers for Disease Control and Prevention (CDC) 1 for routine use in girls aged 11 and 12 years, along with catch-up vaccination for girls and women aged 13—26 years. The …
